Table 2.
Ongoing combination immunotherapy trials in gynecological cancers
| Treatment | Mechanism | Phase | Trial ID | Status |
|---|---|---|---|---|
| Ovarian | ||||
| Upfront | ||||
| Carboplatin/paclitaxel with or without avelumab (JAVELIN) | Chemo/PD-L1 | III | NCT02718417 | Open/not recruiting |
| Carboplatin/paclitaxel/bevacizumab/atezolizumab vs. placebo (IMAGYN50) | Chemo/VEGF/PD-L1 | III | NCT03038100 | Open/recruiting |
| Maintenance rucaparib + nivolumab vs. rucaparib vs. nivolumab vs. placebo (ATHENA) | PARP/PD1 following chemo | III | NCT03522246 | Open/recruiting |
| Relapsed/refractory | ||||
| Carboplatin/paclitaxel/bevacizumab/atezolizumab vs. placebo (ATALANTE) | Chemo/VEGF/PD-L1 | III | NCT02891824 | Open/recruiting |
| Nivolumab/ipilimumab vs. nivolumab (NRG) | PD1/CTLA-4 | II | NCT02498600 | Open/not recruiting |
| PLD + avelumab vs. avelumab vs. PLD (JAVELIN Ovarian 200) | Chemo/PD-L1 | III | NCT02580058 | Open/not recruiting |
| PLD + durvalumab | Chemo/PD-L1 | I/II | NCT02431559 | Open/not recruiting |
| Chemo/bevacizumab/atezolizumab vs. placebo | Chemo/VEGF/PD-L1 | III | NCT03353831 | Not yet recruiting |
| PLD/bevacizumab/atezolizumab vs. PLD/atezolizumab vs. PLD/bevacizumab | Chemo/VEGF/PD-L1 | II/III | NCT02839707 | Open/recruiting |
| Cervical | ||||
| Pembrolizumab/RT/cisplatin (PAPAYA) | PD1/Chemo/RT | I | NCT03144466 | Open/recruiting |
| Atezolizumab + CRT (NRG GY017) | PD-L1/Chemo/RT | III | pending | Pending |
| Atezolizumab + bevacizumab | PD-L1/VEGF | II | NCT02921269 | Open, not recruiting |
| Endometrial | ||||
| Carboplatin/paclitaxel/pembrolizumab | Chemo/PD1 | II | NCT02549209 | Open/recruiting |
| Carboplatin/paclitaxel/pembrolizumab vs. placebo (NRG-GY018) | Chemo/PD1 | III | pending | Pending |
| Durvalumab + tremelimumab vs. durvalumab | PD-L1/CTLA-4 | II | NCT03015129 | Open/recruiting |
PD1 programmed death ligand 1, CTLA-4 CTL antigen-4, PLD pegylated liposomal doxorubicin, CRT chemoradiotherapy